-

09:41:44 PM

CEMI Stock News

CEMI - Chembio Diagnostics Inc.

09/22/21 8:00 AM

Nasdaq : CEMI

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use

RHEA-AI

neutral

08/27/21 8:00 AM

Nasdaq : CEMI

covid-19

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care

RHEA-AI

neutral

08/05/21 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports Second Quarter 2021 Financial Results

Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Achieved

RHEA-AI

neutral

07/22/21 5:03 PM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday,

RHEA-AI

neutral

07/22/21 12:49 PM

Nasdaq : CEMI

Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported by

RHEA-AI

neutral

07/20/21 10:56 PM

Nasdaq : CEMI

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2

RHEA-AI

neutral

05/06/21 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports First Quarter 2021 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2021. Chembio achieved first quarter 2021 total revenue of $8.7

RHEA-AI

positive

04/22/21 8:00 AM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report First Quarter 2021 Financial Results on May 6, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2021 after the close of trading on Thursday,

RHEA-AI

neutral

04/01/21 5:30 PM

Nasdaq : CEMI

covid-19

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on

RHEA-AI

neutral

03/11/21 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2020. Recent Accomplishments & Highlights Achieved

RHEA-AI

positive

CEMI Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.chembio.com
Security nameChembio Diagnostics Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees355
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Pharmaceutical Preparation Manufacturing

CEMI Description:

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.